Neurological Surgery 脳神経外科50巻1号

2022年01月発行

特集 Precision Medicine—個別化医療を目指した遺伝子診断と新治療の知見 Ⅱ良性脳腫瘍

頭蓋咽頭腫—分子標的治療の知見

著者： 田中將太¹ 高柳俊作¹ 髙見浩数¹ 齊藤延人¹

所属機関： ¹東京大学大学院医学系研究科脳神経外科

ページ範囲：P.171 - P.178

Point
・網羅的遺伝子解析により，乳頭上皮型頭蓋咽頭腫の大半にBRAF-V600E変異がみられることが判明した．
・他癌腫で承認済のBRAF阻害薬，MEK阻害薬が，BRAF変異陽性乳頭上皮型頭蓋咽頭腫に著効するという症例報告がなされた．
・頭蓋咽頭腫は難治な脳腫瘍であり，乳頭上皮型においては従来の手術・放射線治療に分子標的治療を加えた集学的治療が重要となろう．

参考文献

1）Narita Y, Shibui S；Committee of Brain Tumor Registry of Japan Supported by the Japan Neurosurgical Society：Trends and outcomes in the treatment of gliomas based on data during 2001-2004 from the Brain Tumor Registry of Japan. Neurol Med Chir（Tokyo）55（Suppl 1）：286-295, 2015

2）Müller HL, et al：Craniopharyngioma. Nat Rev Dis Primers 5：75, 2019

3）Brastianos PK, et al：Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46：161-165, 2014

4）Brastianos PK, et al：Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst 108：djv310, 2015

5）Gupta DK, et al：Recurrence in craniopharyngiomas：analysis of clinical and histological features. J Clin Neurosci 13：438-442, 2006

6）Prieto R, et al：Craniopharyngioma recurrence：the impact of tumor topography. J Neurosurg 125：1043-1049, 2016

7）Larkin SJ, et al：BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Acta Neuropathol 127：927-929, 2014

8）Kleinschmidt-DeMasters BK, et al：Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37：685-698, 2013

9）Schindler G, et al：Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121：397-405, 2011

10）Su F, et al：RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366：207-215, 2012

11）Long GV, et al：Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371：1877-1888, 2014

12）Robert C, et al：Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372：30-39, 2015

13）Schreck KC, et al：RAF and MEK inhibitor therapy in adult patients with brain tumors：a case-based overview and practical management of adverse events. Neurooncol Pract 7：369-375, 2020

mutant brain tumors：Pacific Pediatric Neuro-Oncology Consortium study（PNOC-002）. Oncotarget 11：1942-1952, 2020

15）Nobre L, et al：Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol 4：PO.19.00298, 2020

16）Juratli TA, et al：Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer 125：2910-2914, 2019

17）Aylwin SJ, et al：Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary 19：544-546, 2016

18）Roque A, Odia Y：BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol 6：95-99, 2017

19）Rostami E, et al：Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochir（Wien）159：2217-2221, 2017

20）Rao M, et al：Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib：a case report. Oncotarget 10：6038-6042, 2019

21）Himes BT, et al：Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib：case report. J Neurosurg 130：1299-1303, 2019（Online Publication Date 27 Apr 2018）

22）Khaddour K, et al：Successful use of BRAF/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma. J Natl Compr Canc Netw 18：1590-1595, 2020

23）Di Stefano AL, et al：Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma. Neurooncol Adv 2：vdaa141, 2020

24）Bernstein A, et al：Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors：a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity. J Neurosurg 133：1704-1709, 2020（Online Publication Date：1 Nov 2019）

25）Fujio S, et al：A clinical rule for preoperative prediction of BRAF mutation status in craniopharyngiomas. Neurosurgery 85：204-210, 2019